Sector News

Pfizer buys infectious disease biotech Amplyx

May 1, 2021
Life sciences

Pharmaceutical industry leaders are increasingly focused on infectious diseases amid the COVID-19 pandemic and growing concern over treatment-resistant superbugs. In July, a group of drugmakers including Pfizer announced they raised almost $1 billion for a partnership promising to deliver two to four new antibiotics by 2030.

Apart from vaccines, Pfizer’s anti-infective pipeline was thin before the Amplyx acquisition, with a treatment for COVID-19 in Phase 1 studies and an antibiotic in Phase 3. But the company’s head of hospital products, Angela Lukin, said Wednesday that Pfizer is “deeply committed” to its infectious disease program.

Fosmanogepix could prove to be a weapon against fungal infections because of its mechanism of action, Pfizer said. The Food and Drug Administration hasn’t approved a new class of antifungal therapies in almost 20 years. Researchers are currently studying both oral and intravenous forms of the drug, which in theory would help patients transition from the hospital to home. READ MORE

By Kristin Jensen

Source: biopharmadive.com

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach